Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Garadacimab by CSL for Idiopathic Pulmonary Fibrosis: Likelihood of Approval
Garadacimab is under clinical development by CSL and currently in Phase II for Idiopathic Pulmonary Fibrosis. According to GlobalData, Phase...
Garadacimab by CSL for Idiopathic Pulmonary Fibrosis: Likelihood of Approval
Garadacimab is under clinical development by CSL and currently in Phase II for Idiopathic Pulmonary Fibrosis. According to GlobalData, Phase...
Garadacimab by CSL for Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency): Likelihood of Approval
Garadacimab is under clinical development by CSL and currently in Pre-Registration for Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency)....